Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Robin

Showing results (231-240 of 298) with videos related to

Pageof 30
Sort By:
Bone Marrow Transplantation|March 26, 2021
Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groupsMarie Robin, Raphael Porcher, Corentin Orvain, et al.
Leukemia & Lymphoma|April 19, 2019
A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation<sup>.</sup>Eline M P Cremers, Theo de Witte, Liesbeth de Wreede, et al.
Haematologica|January 19, 2019
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantationNico Gagelmann, Diderik-Jan Eikema, Matthias Stelljes, et al.
Blood|August 5, 2024
Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDSEsteban Arrieta-Bolaños, Lars L J van der Burg, Tobias Gedde-Dahl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 11, 2016
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMTSilke Heidenreich, Dimitris Ziagkos, Liesbeth C de Wreede, et al.
Blood Advances|January 4, 2018
Haploidentical transplant in patients with myelodysplastic syndromeMarie Robin, Raphael Porcher, Fabio Ciceri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 3, 2018
HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry AnalysisMarie Robin, Raphaël Porcher, Annalisa Ruggeri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 28, 2014
Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular TherapyRémy Duléry, Mohamad Mohty, Alain Duhamel, et al.
Bone Marrow Transplantation|October 15, 2025
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMTPatryk Sobieralski, Tomasz Czerw, Luuk Gras, et al.
Bone Marrow Transplantation|April 23, 2022
Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Katya Mauff, Dietrich Beelen, et al.
Pageof 30

Showing results (231-240 of 298) with videos related to

Sort By:
Pageof 30
Bone Marrow Transplantation|March 26, 2021
Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groupsMarie Robin, Raphael Porcher, Corentin Orvain, et al.
Leukemia & Lymphoma|April 19, 2019
A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation<sup>.</sup>Eline M P Cremers, Theo de Witte, Liesbeth de Wreede, et al.
Haematologica|January 19, 2019
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantationNico Gagelmann, Diderik-Jan Eikema, Matthias Stelljes, et al.
Blood|August 5, 2024
Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDSEsteban Arrieta-Bolaños, Lars L J van der Burg, Tobias Gedde-Dahl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 11, 2016
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMTSilke Heidenreich, Dimitris Ziagkos, Liesbeth C de Wreede, et al.
Blood Advances|January 4, 2018
Haploidentical transplant in patients with myelodysplastic syndromeMarie Robin, Raphael Porcher, Fabio Ciceri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 3, 2018
HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry AnalysisMarie Robin, Raphaël Porcher, Annalisa Ruggeri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 28, 2014
Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular TherapyRémy Duléry, Mohamad Mohty, Alain Duhamel, et al.
Bone Marrow Transplantation|October 15, 2025
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMTPatryk Sobieralski, Tomasz Czerw, Luuk Gras, et al.
Bone Marrow Transplantation|April 23, 2022
Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Katya Mauff, Dietrich Beelen, et al.
Pageof 30